Background and Objectives: Fungi, particularly Aspergillus and Candida species, are increasingly found in cystic fibrosis (CF) airway fluids. However, their association with other CF pathogens, medications and lung function, especially in CF children, remains elusive. We analyzed the relationship of fungal colonization to microbiological and clinical parameters of pediatric CF patients. Methods and Results: Fungal colonization and long-term clinical parameters like BMI and lung function were retrospectively studied in over 500 CF patients. Colonization was defined based on Chotirmall et al. (Chest 2010). Candida albicans (CA) was the most prevalent fungus detected in CF airway fluids, followed by C. non-albicans > Aspergillus fumigatus (AF) > A. non-fumigatus species. We found an association between fungal colonization and (among other parameters) bacterial co-colonization, lung function, BMI and antibiotic therapy. Conclusion: This study suggests that colonization with CA or AF is affected by bacterial co-colonization and may modulate the disease severity already in pediatric CF patients.
Objectives:
Pneumocystis jirovecii is an atypical fungus that causes pneumonia in immunocompromised patients. Its role in patients with CF is unclear. Its reported prevalence in CF ranges from 1−22% but has never been determined in UK centres. Here we present preliminary cross sectional data from an ongoing study at a single UK adult CF centre serving over 400 patients, in order to establish potential risk and protective factors for infection. Methods: Sputum samples were obtained from randomly selected CF patients and sent for routine microbiology and Pneumocystis PCR assay. Symptom scores, spirometry and inflammatory markers were measured and prophylactic and recent antibiotic therapy data recorded. Results: To date, 36 patients have been recruited. The mean age was 29.9±10.6 years, mean % predicted FEV1 52.1±17.0%. Chronic infecting organisms included P. aeruginosa (64% of patients), S. aureus (44%), B. cepacia complex (17%), Ralstonia spp. (6%) and M. abscessus (6%). Prophylactic azithromycin was taken by 28 (78%) of patients, 9 patients 25%) had received co-trimoxazole in the previous 3 months. Only 3 patients (8%) were neither on prophylactic azithromycin nor received co-trimoxazole in the past 3 months. 1 subject had a weakly positive PCR, 2 subjects' samples were inhibitory for PCR and the remaining 33 subjects had negative PCR results. Conclusion: Current patient numbers are small but preliminary results suggest that Pneumocystis jirovecii is not an important infecting pathogen in our cohort of patients. This may be due to frequent use co-trimoxaxole for pulmonary exacerbations and high prevalence of prophylactic azithromycin at our centre compared to published studies. Further studies are required to determine the mode of acquisition of infection with these strains, and whether there is a common environmental source of infection or cross infection between patients.
